Focused On-demand Library for Ribonuclease H2 subunit A

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
O75792

UPID:
RNH2A_HUMAN

ALTERNATIVE NAMES:
Aicardi-Goutieres syndrome 4 protein; RNase H(35); Ribonuclease HI large subunit; Ribonuclease HI subunit A

ALTERNATIVE UPACC:
O75792; B2RCY1; Q96F11

BACKGROUND:
The enzyme Ribonuclease H2 subunit A, known for its catalytic activity in degrading RNA:DNA hybrids, is crucial for DNA replication. It ensures the fidelity of DNA replication by removing RNA primers and ribonucleotides, preventing genomic instability.

THERAPEUTIC SIGNIFICANCE:
Given its association with Aicardi-Goutieres syndrome 4, characterized by profound neurological impairments, Ribonuclease H2 subunit A represents a promising avenue for therapeutic research. Targeting its enzymatic activity could offer new strategies for managing this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8440 of 8789